

Acute Bacterial Skin and Skin Structure Infections (ABSSIs) Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025 - 2034

<https://marketpublishers.com/r/A5B5C9CD46C7EN.html>

Date: March 2025

Pages: 130

Price: US\$ 4,850.00 (Single User License)

ID: A5B5C9CD46C7EN

Abstracts

The Global Acute Bacterial Skin And Skin Structure Infections Market reached USD 1.3 billion in 2024 and is projected to expand at a CAGR of 5% between 2025 and 2034.

The market is poised for steady growth, driven by rising bacterial resistance, the increasing prevalence of skin and soft tissue infections, and rapid advancements in antibiotic formulations and delivery methods. A growing number of immunocompromised individuals, including patients undergoing chemotherapy or organ transplantation, are contributing to the escalating demand for effective treatment options. The surge in chronic diseases such as diabetes and peripheral vascular disorders, which make patients more susceptible to complicated skin infections, is further supporting market expansion.

Additionally, growing awareness regarding early diagnosis and treatment of skin infections, coupled with the development of innovative therapies targeting resistant pathogens, is significantly shaping the market outlook. Pharmaceutical companies are investing heavily in research and development to launch novel antibiotics capable of tackling multidrug-resistant organisms like MRSA (Methicillin-resistant *Staphylococcus aureus*), which remains a major concern globally. This has led to the introduction of more advanced antibiotics, including glycopeptides, oxazolidinones, and lipopeptides, that offer targeted action against resistant bacteria, improving patient outcomes and enhancing treatment success rates.

The market is segmented into two primary categories based on infection type: community-acquired and hospital-acquired ABSSIs. Community-acquired infections accounted for a dominant 64.3% share in 2024, as these infections are far more prevalent in the general population and often occur outside hospital environments. Conditions such as cellulitis, wound infections, and abscesses contribute significantly to the number of cases seen annually. These infections frequently require medical

intervention but are typically managed in outpatient settings, creating sustained demand for effective and easily administrable antibiotic therapies. With the rising incidence of skin injuries and compromised skin integrity due to lifestyle diseases, the community-acquired segment continues to drive notable growth in the ABSSSIs market. Based on drug administration routes, the market is classified into parenteral, oral, and topical formulations. The parenteral segment is projected to generate USD 1 billion by 2034, maintaining its stronghold as the preferred route for delivering antibiotics, especially in severe and complicated cases. Parenteral administration, which delivers antibiotics directly into the bloodstream, remains critical for treating life-threatening ABSSSIs caused by multidrug-resistant pathogens. It enables rapid therapeutic action and is especially vital for hospital-acquired infections and patients in intensive care units, where timely intervention is crucial to avoid systemic complications. The U.S. Acute Bacterial Skin and Skin Structure Infections (ABSSSIs) market was valued at USD 476.3 million in 2024, largely driven by the high incidence of skin infections and rising chronic health conditions, including diabetes and obesity, which elevate the risk of developing ABSSSIs. An aging population, more prone to skin infections due to weakened immune defenses, continues to influence market dynamics. Moreover, the persistent challenge posed by multidrug-resistant bacteria, particularly MRSA, sustains the demand for advanced, next-generation antibiotic therapies and supports continued market growth in the U.S.

Contents

CHAPTER 1 METHODOLOGY AND SCOPE

- 1.1 Market scope and definition
- 1.2 Research design
 - 1.2.1 Research approach
 - 1.2.2 Data collection methods
- 1.3 Base estimates and calculations
 - 1.3.1 Base year calculation
 - 1.3.2 Key trends for market estimation
- 1.4 Forecast model
- 1.5 Primary research and validation
 - 1.5.1 Primary sources
 - 1.5.2 Data mining sources

CHAPTER 2 EXECUTIVE SUMMARY

- 2.1 Industry 360° synopsis

CHAPTER 3 INDUSTRY INSIGHTS

- 3.1 Industry ecosystem analysis
- 3.2 Industry impact forces
 - 3.2.1 Growth drivers
 - 3.2.1.1 Increasing incidence of ABSSSIs
 - 3.2.1.2 Advancements in antibiotic development and expanding number of pipeline drugs
 - 3.2.1.3 Rising healthcare investments and improved access to medical treatments
 - 3.2.2 Industry pitfalls and challenges
 - 3.2.2.1 High cost of novel antibiotics
 - 3.2.2.2 Side effects associated with certain antibiotics
- 3.3 Growth potential analysis
- 3.4 Regulatory landscape
- 3.5 Pipeline analysis
- 3.6 Porter's analysis
- 3.7 PESTEL analysis

CHAPTER 4 COMPETITIVE LANDSCAPE, 2024

- 4.1 Introduction
- 4.2 Company matrix analysis
- 4.3 Competitive analysis of major market players
- 4.4 Competitive positioning matrix
- 4.5 Strategy dashboard

CHAPTER 5 MARKET ESTIMATES AND FORECAST, BY INFECTION TYPE, 2021 – 2034 (\$ MN)

- 5.1 Key trends
- 5.2 Community-acquired ABSSSI
- 5.3 Hospital- acquired ABSSSI

CHAPTER 6 MARKET ESTIMATES AND FORECAST, BY DRUG CLASS, 2021 – 2034 (\$ MN)

- 6.1 Key trends
- 6.2 Glycopeptides/lipoglycopeptides
- 6.3 Oxazolidinones
- 6.4 Beta-lactams
- 6.5 Lipopeptide
- 6.6 Tetracyclines
- 6.7 Other drug classes

CHAPTER 7 MARKET ESTIMATES AND FORECAST, BY ROUTE OF ADMINISTRATION, 2021 – 2034 (\$ MN)

- 7.1 Key trends
- 7.2 Parenteral
- 7.3 Oral
- 7.4 Topical

CHAPTER 8 MARKET ESTIMATES AND FORECAST, BY DISTRIBUTION CHANNEL, 2021 – 2034 (\$ MN)

- 8.1 Key trends
- 8.2 Hospital pharmacies
- 8.3 Retail pharmacies

8.4 Online pharmacies

CHAPTER 9 MARKET ESTIMATES AND FORECAST, BY REGION, 2021 – 2034 (\$ MN)

9.1 Key trends

9.2 North America

9.2.1 U.S.

9.2.2 Canada

9.3 Europe

9.3.1 Germany

9.3.2 UK

9.3.3 France

9.3.4 Italy

9.3.5 Spain

9.3.6 Netherlands

9.4 Asia Pacific

9.4.1 China

9.4.2 Japan

9.4.3 India

9.4.4 Australia

9.4.5 South Korea

9.5 Latin America

9.5.1 Brazil

9.5.2 Mexico

9.5.3 Argentina

9.6 Middle East and Africa

9.6.1 South Africa

9.6.2 Saudi Arabia

9.6.3 UAE

CHAPTER 10 COMPANY PROFILES

10.1 AbbVie

10.2 Basilea Pharmaceutica

10.3 Cipher Pharmaceuticals

10.4 Endo Pharmaceuticals

10.5 Glenmark Pharmaceuticals

10.6 Melinta Therapeutics

- 10.7 Menarini Group
- 10.8 Merck
- 10.9 Nabriva Therapeutics
- 10.10 Paratek Pharmaceuticals
- 10.11 Pfizer
- 10.12 Sandoz

I would like to order

Product name: Acute Bacterial Skin and Skin Structure Infections (ABSSIs) Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025 - 2034

Product link: <https://marketpublishers.com/r/A5B5C9CD46C7EN.html>

Price: US\$ 4,850.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/A5B5C9CD46C7EN.html>